Yes, prednisone can be given to patients with multiple sclerosis—it is specifically indicated for treating acute MS relapses.
Prednisone and other corticosteroids are standard therapy for acute exacerbations of multiple sclerosis. The FDA-approved labeling explicitly states that for MS relapses, daily doses of 200 mg of prednisolone (equivalent to prednisone) for one week followed by 80 mg every other day for one month have been shown to be effective 1. This establishes prednisone as a legitimate treatment option for MS patients experiencing acute relapses.
Clinical Context and Evidence
The use of corticosteroids in MS is well-established for acute relapse management:
High-dose corticosteroids accelerate recovery from acute MS exacerbations 2. While they speed resolution of relapses, they do not alter the ultimate outcome or natural history of the disease 1.
Recent evidence suggests corticosteroid treatment may reduce long-term disability risk. A 2025 study of 3,673 MS patients found that steroid-treated relapses were associated with lower risk of confirmed disability worsening compared to untreated relapses (HR 1.50 vs 1.72), suggesting treatment impacts not just recovery speed but also residual structural damage 3.
Practical Administration
Oral prednisone is a viable alternative to IV methylprednisolone:
Bioavailability studies demonstrate that 1,250 mg oral prednisone is bioequivalent to 1 gram IV methylprednisolone 4.
Patient compliance with high-dose oral prednisone (1,250 mg daily) is excellent at 94.3%, with most patients preferring oral therapy for convenience 5, 6.
The typical regimen involves 1,250 mg daily for 3-5 days, though the FDA label describes 200 mg daily for 7 days followed by 80 mg every other day for 1 month 1.
Important Caveats
The oral prednisone taper following IV steroids is controversial and may not be necessary:
Studies show that oral prednisone taper after IV methylprednisolone does not improve neurologic outcomes at 12 months compared to IV therapy alone 7.
A pilot trial found no signs of adrenal insufficiency without tapering, but patients on taper experienced more mood disorders, hyperglycemia, and weight gain 8.
Monitoring considerations for MS patients on corticosteroids:
- Avoid abrupt withdrawal after long-term therapy 1.
- Monitor for psychiatric effects (mood changes, depression, psychosis) 1.
- Consider osteoporosis prevention if treatment exceeds 3 months at ≥5 mg prednisone equivalent 1.
- Patients on disease-modifying therapies should continue them; the efficacy of DMTs may modify the benefit of steroid treatment 3.
Timing matters: Treatment should ideally begin within the first 14 days of relapse onset, with benefit reported up to 6 weeks 9.